Business Context and Reporting Period
Filing identity: The source text is a Form 10-Q for Nile Therapeutics, Inc., not Capricor Therapeutics, Inc. It covers the quarter and nine months ended September 30, 2011, and was filed November 14, 2011.
Nile was a development-stage biopharmaceutical company developing cardiovascular products. Its lead candidate was cenderitide for heart failure, supported by a Phase 1 collaboration with Medtronic, and its second candidate, CU-NP, remained preclinical. The company had no product sales or product revenue.
Key Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Collaboration income | $813,000 in 2011; none in 2010 | $1,159,000 in 2011; none in 2010 |
| Research and development expense | $1,470,091 vs. $1,148,641 | $2,795,354 vs. $3,517,822 |
| General and administrative expense | $499,273 vs. $664,095 | $1,597,855 vs. $1,732,745 |
| Net loss | $1,144,073 vs. $1,809,493 | $3,220,396 vs. $5,235,834 |
| Loss per share | $0.03 vs. $0.05 | $0.09 vs. $0.17 |
| Net cash used in operating activities | Not separately presented | $3,080,632 vs. $3,262,791 |
- Cash and cash equivalents were $2.61 million at September 30, 2011, down from $3.38 million at December 31, 2010.
- Working capital was approximately $2.31 million; current liabilities were $717,817.
- Total assets were $3.09 million and stockholders’ equity was $2.37 million at September 30, 2011.
- The company had no debt reported in current liabilities and no off-balance-sheet arrangements. Historical notes payable had been repaid or converted before the current period.
- Accumulated deficit was $43.15 million at September 30, 2011.
- Employee stock-based compensation was $686,711 for the nine-month period and $248,996 for the quarter.
Material Changes Versus the Prior Comparable Period
- Collaboration income increased from zero to $813,000 for the quarter and $1.16 million for the nine months, reflecting Medtronic reimbursements and milestone-related activity under the Phase 1 trial agreement.
- Quarterly R&D expense increased approximately 28% to $1.47 million, primarily due to cenderitide toxicology work and Medtronic-sponsored Phase 1 clinical costs.
- Nine-month R&D expense declined approximately 21% because the prior-year period included costs associated with the Phase 2 cenderitide study, completed in the fourth quarter of 2010.
- G&A expense declined approximately 10% for both the quarter and nine months, principally due to lower stock compensation and the absence of certain 2010 Nasdaq listing charges.
- Nine-month net loss improved by approximately $2.02 million, largely because of collaboration income and lower R&D and G&A spending.
- Cash decreased by $770,819 during the first nine months of 2011, compared with a $1.26 million increase in the prior-year period. Financing provided $2.31 million in 2011, versus $4.52 million in 2010.
- In June 2011, the company sold 5.0 million units for gross proceeds of $2.5 million, consisting of common shares and warrants. Net proceeds were approximately $2.30 million.
- The company’s securities were suspended from Nasdaq trading in May 2011 and formally delisted in July 2011.
Guidance, Outlook, Risks and Unusual Items
- Management expected existing resources to fund operations only into the second quarter of 2012, based on the plan to complete the cenderitide Phase 1 trial.
- Forecast average monthly cash expenditures for the following six months, net of Medtronic funding, were approximately $300,000.
- The company expected to complete remaining Phase 1 activities, including data analysis and the study report, during the first quarter of 2012. It planned a larger Phase 2 cenderitide trial in 2012, subject to the Phase 1 results, but required substantial additional capital to proceed.
- Management stated that the liquidity situation raised substantial doubt about the company’s ability to continue as a going concern. The financial statements were nevertheless prepared on a going-concern basis without adjustments for a possible failure to continue operations.
- Potential funding sources included equity or debt financings, strategic collaborations and licensing transactions. No committed source of additional financing existed at the filing date.
- Additional equity financing could materially dilute existing stockholders; debt financing could add interest costs and restrictive covenants; licensing or collaboration transactions could require relinquishing rights on unfavorable terms.
- Cenderitide licenses carried potential contingent milestone payments of up to $31.9 million, and CU-NP licenses carried potential milestone payments of up to $24.3 million, subject to specified development and regulatory achievements.
- The Medtronic agreement created potential jointly owned intellectual property and royalty obligations. It also restricted third-party development or commercialization arrangements until the earlier of specified dates, expected to be February 2012 based on the anticipated database delivery.
- The company reported no material pending legal proceedings. Management concluded that disclosure controls and procedures were effective at the reasonable assurance level.
Investor Verification Priorities
- Verify the issuer identity: the supplied filing is for Nile Therapeutics, Inc., while the request metadata identifies Capricor Therapeutics, Inc.
- Confirm current liquidity, monthly cash burn and whether financing was obtained before the projected second-quarter 2012 funding shortfall.
- Review the outcome of the cenderitide Phase 1 trial, including safety, efficacy, endpoints and whether the planned Phase 2 study proceeded.
- Assess the terms, continuation and economics of the Medtronic collaboration, including reimbursement, joint intellectual property and potential royalties.
- Evaluate dilution from the 2011 offering, outstanding warrants and stock options, including approximately 8.66 million outstanding warrants and 7.84 million outstanding options at September 30, 2011.
- Review the going-concern disclosure and the company’s ability to fund its licensed milestone obligations and ongoing development programs.